Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut
This article was originally published in The Tan Sheet
Executive Summary
The House Energy and Commerce Health subcommittee unanimously advances the Sunscreen Innovation Act to full committee, but provisions in the bill seeking a tight timeline for FDA’s review of sunscreen ingredient TEAs are in limbo, according to the Public Access to Sunscreens coalition of stakeholders.
You may also be interested in...
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen TEA could concern advocates on Capitol Hill and in the industry for using the process for adding ingredients to the OTC sunscreen monograph.
FDA Sunscreen Decision Deadlines, Expedited TEAs Proposed
The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.
Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024
Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.